UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,034	08/08/2008	Stefan Golz	004974.01217	3230
22907 7590 02/10/2009 BANNER & WITCOFF, LTD. 1100 13th STREET, N.W.			EXAMINER	
			CHEU, CHANGHWA J	
SUITE 1200 WASHINGTON, DC 20005-4051			ART UNIT	PAPER NUMBER
			1641	
			MAIL DATE	DELIVERY MODE
			02/10/2009	PAPER

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/594,034	GOLZ ET AL.
Office Action Summary	Examiner	Art Unit
	JACOB CHEU	1641
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION  .136(a). In no event, however, may a reply be tind  d will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. mely filed I the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 6/1  2a) This action is <b>FINAL</b> . 2b) Th  3) Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4)  Claim(s) 1-18 and 21-23 is/are pending in the 4a) Of the above claim(s) is/are withdra 5)  Claim(s) is/are allowed.  6)  Claim(s) is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) 1-18 and 21-23 are subject to restrict	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examir 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre 11) The oath or declaration is objected to by the E	ccepted or b) objected to by the edrawing(s) be held in abeyance. Se ction is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig     a) All b) Some * c) None of:     1. Certified copies of the priority documer     2. Certified copies of the priority documer     3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat ority documents have been receiv au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	ate

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4-11, drawn to a method of screening for therapeutic agent, with a special technical feature of detecting the binding of the compound to the PPARA peptide.

Group II, claim(s) 2, drawn to a method of screening for therapeutic agent, with a special technical feature of determining the activity of the PPARA peptide at a concentration of the test compound.

Group III, claim(s) 3, drawn to a method of screening for therapeutic agent, with a special technical feature of of determining the activity of the PPARA peptide at a concentration of a known regulator of TPP2peptide.

Group IV, claim(s) 12-17, drawn to drawn to a method of screening for therapeutic agent, with a special technical feature of detecting the binding of the test compound to the PPARA polynucleotide.

Group V, claim(s) 18, drawn to drawn to a method of screening for therapeutic agent, with a special technical feature of detecting the amount of PPARA peptide.

Group VI, claim(s) 21, drawn to a pharmaceutical composition which regulates the activity of the PPARA.

Group VII, claim(s) 22-23, drawn to a pharmaceutical composition comprising PPARA.

Application/Control Number: 10/594,034 Page 3

Art Unit: 1641

2. The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

With respect to Group VII, Hudson et al. teach a PPARA polynucleotide and polypeptide (See SEQ ID No. 1 and SEQ ID No. 2). Furthermore, each group contains special technical feature not required by the other group.

Therefore, the invention of Group I-VII do not fulfill the requirement for unity of invention under Rule 13.1 PCT. Accordingly, the method of preparing or analyzing or are not so linked as to form a single general inventive concept.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 10/594,034 Page 4

Art Unit: 1641

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacob Cheu whose telephone number is 571-272-0814. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jacob Cheu/

Examiner, Art Unit 1641